Novel Biomarkers of AKI in Cirrhosis.

IF 4.3 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Seminars in liver disease Pub Date : 2022-11-01 DOI:10.1055/a-1954-4136

Adrià Juanola, Ann T Ma, Elisa Pose, Pere Ginès

{"title":"Novel Biomarkers of AKI in Cirrhosis.","authors":"Adrià Juanola, Ann T Ma, Elisa Pose, Pere Ginès","doi":"10.1055/a-1954-4136","DOIUrl":null,"url":null,"abstract":"<p><p>Acute kidney injury (AKI) is a frequent complication in patients with cirrhosis that is associated with poor outcomes and decreased survival. The definition of AKI in cirrhosis is currently based on changes of serum creatinine levels with respect to baseline values. Differential diagnosis of the causes of AKI is of major relevance, considering that some causes of AKI, such as hepatorenal syndrome, have specific treatment options and different prognosis. Prediction of kidney function recovery and patients' survival is also crucial in this patient population to guide clinical decisions. AKI biomarkers in cirrhosis have emerged as a promising tool for differential diagnosis and prognosis in this situation. There are consistent data showing that some urine biomarkers, particularly neutrophil gelatinase-associated lipocalin, may be useful in daily clinical practice for the differential diagnosis of the cause of AKI in cirrhosis. AKI biomarkers may constitute a useful tool for use in differential diagnosis, prognosis of renal function, and survival in patients with cirrhosis. This review focuses on the current state of knowledge and future perspective of novel biomarkers of AKI in cirrhosis.</p>","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"42 4","pages":"489-500"},"PeriodicalIF":4.3000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in liver disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-1954-4136","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Acute kidney injury (AKI) is a frequent complication in patients with cirrhosis that is associated with poor outcomes and decreased survival. The definition of AKI in cirrhosis is currently based on changes of serum creatinine levels with respect to baseline values. Differential diagnosis of the causes of AKI is of major relevance, considering that some causes of AKI, such as hepatorenal syndrome, have specific treatment options and different prognosis. Prediction of kidney function recovery and patients' survival is also crucial in this patient population to guide clinical decisions. AKI biomarkers in cirrhosis have emerged as a promising tool for differential diagnosis and prognosis in this situation. There are consistent data showing that some urine biomarkers, particularly neutrophil gelatinase-associated lipocalin, may be useful in daily clinical practice for the differential diagnosis of the cause of AKI in cirrhosis. AKI biomarkers may constitute a useful tool for use in differential diagnosis, prognosis of renal function, and survival in patients with cirrhosis. This review focuses on the current state of knowledge and future perspective of novel biomarkers of AKI in cirrhosis.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肝硬化AKI的新生物标志物。

急性肾损伤(AKI)是肝硬化患者常见的并发症，与预后不良和生存率降低有关。肝硬化AKI的定义目前是基于血清肌酐水平相对于基线值的变化。考虑到一些引起AKI的原因，如肝肾综合征，有特定的治疗方案和不同的预后，鉴别诊断AKI的病因具有重要意义。预测肾功能恢复和患者生存对指导临床决策也至关重要。在这种情况下，肝硬化AKI生物标志物已成为鉴别诊断和预后的有希望的工具。有一致的数据表明，一些尿液生物标志物，特别是中性粒细胞明胶酶相关的脂钙蛋白，可能在日常临床实践中对肝硬化AKI病因的鉴别诊断有用。AKI生物标志物可能是用于肝硬化患者鉴别诊断、肾功能预后和生存的有用工具。本文综述了肝硬化AKI的新生物标志物的现状和未来展望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Seminars in liver disease 医学-胃肠肝病学

CiteScore

8.20

自引率

2.40%

发文量

期刊介绍： Seminars in Liver Disease is a quarterly review journal that publishes issues related to the specialties of hepatology and gastroenterology. As the premiere review journal in the field, Seminars in Liver Disease provides in-depth coverage with articles and issues focusing on topics such as cirrhosis, transplantation, vascular and coagulation disorders, cytokines, hepatitis B & C, Nonalcoholic Steatosis Syndromes (NASH), pediatric liver diseases, hepatic stem cells, porphyrias as well as a myriad of other diseases related to the liver. Attention is also given to the latest developments in drug therapy along with treatment and current management techniques. Seminars in Liver Disease publishes commissioned reviews. Unsolicited reviews of an exceptional nature or original articles presenting remarkable results will be considered, but case reports will not be published.

期刊最新文献

Role of the Gut Microbiome in Metabolic Dysfunction-Associated Steatotic Liver Disease. HBV Biomarkers and Their Role in Guiding Treatment Decisions. Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease. Managing Multiorgan Failure in Acute on Chronic Liver Failure. Advancements in MELD score and its impact in Hepatology.